Changes in drug survival of adalimumab over time in patients with psoriasis: a nationwide cohort study

View at publisher Summarise with VIRAT
Authors: Gustav Hjort, C. Schwarz, Lars Erik Bryld, Kawa Khaled Ajgeiy, Mads Kirchheiner Rasmussen, Trine Bertelsen, Kasper Fjellhaugen Hjuler, Tomas Norman Dam, Nikolai Loft, Prof. Lone Skov
Cited by: 0
References: 22

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

BACKGROUND: Drug survival of older biologic therapies is thought to be influenced by the availability of newer biologic therapies and lower-cost biosimilars. However, there are limited data examining changes in drug survival over time. OBJECTIVES: To examine the drug survival of adalimumab over the past two decades. METHODS: This observational, retrospective, multicentre cohort study analysed data from patients with moderate-to-severe psoriasis treated with adalimumab registered in the Danish nationwide registry, DERMBIO. Patients were stratified into two distinct time periods based on initiation date: an early period (2007-2016) and a late period (2019-2024). Kaplan-Meier curves were used to present unadjusted drug survival curves. A multivariable adjusted Cox proportional hazards model was used to compare the risk of drug discontinuation between the two periods. RESULTS: In total, 2336 patients were included: 861 in the early period and 1475 in the late period. We found a significantly lower risk of drug discontinuation in the late period compared with the early period (adjusted hazard ratio 0.78, 95% confidence interval 0.68-0.90, P < 0.001), despite the concurrent availability of newer and more effective biologic therapies. CONCLUSIONS: This study found that the increased number of available biologic therapies did not have a negative impact on the drug survival of adalimumab. On the contrary, discontinuation risk was significantly lower in 2019-2024 compared with 2007-2016. The concurrent introduction of lower-cost biosimilars and the associated rise in dose escalation may have contributed to the improved drug survival observed in the later period.

Fields of Study & Subjects

Psoriasis: Treatment and Pathogenesis Biosimilars and Bioanalytical Methods Spondyloarthritis Studies and Treatments

Publication details

Journal / source
Clinical and Experimental Dermatology
Volume
51
Issue
9
Pages
1621–1628
Publication date
24 March 2026
Language
EN